Relationship of Neoadjuvant Chemotherapy Efficacy with Histopathologic Molecular Subtypes in Breast Cancer Patients

Introduction: Breast cancer is the most common malignancy in women, and it is the second leading cause of malignancy-related mortality in women after lung cancer. Locally advanced breast cancer is a clinically heterogeneous group with a broad spectrum. Neoadjuvant chemotherapy (NAC) is the standard...

Full description

Bibliographic Details
Published in:	İstanbul Medical Journal
Main Authors:	Çiğdem Yıldırım, Fatih Teker, İlker Nihat Ökten, İlkay Gültürk, Aydın Aytekin, Alper Aytekin, Latif Yılmaz, Çiğdem Usul Afşar
Format:	Article
Language:	English
Published:	İstanbul Training and Research Hospital 2024-11-01
Subjects:	breast cancer neoadjuvant chemotherapy molecular subtype pathological response
Online Access:	https://istanbulmedicaljournal.org/articles/relationship-of-neoadjuvant-chemotherapy-efficacy-with-histopathologic-molecular-subtypes-in-breast-cancer-patients/doi/imj.galenos.2024.96266

Similar Items

Prediction of the number of positive axillary lymph nodes according to sentinel lymph node involvement and biological subtypes in patients receiving neoadjuvant chemotherapy
by: Latif Yilmaz, et al.
Published: (2024-07-01)

A study on the impact of neoadjuvant therapy on molecular subtype conversion in breast cancer
by: Run-Ze Zhang, et al.
Published: (2025-04-01)

The Role of Magnetic Resonance Imaging in Predicting Pathological Complete Response in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy
by: İlkay Gültürk, et al.
Published: (2025-03-01)

Peripheral blood lymphocytes subtypes as new predictors for neoadjuvant therapy efficacy in breast cancer
by: Jikun Feng, et al.
Published: (2022-08-01)

Significance of intrinsic breast cancer subtypes on the long-term prognosis after neoadjuvant chemotherapy
by: Wataru Goto, et al.
Published: (2018-11-01)

Prediction of response to neoadjuvant chemotherapy by MammaTyper® across breast cancer subtypes: A retrospective cross-sectional study
by: Francesco Schettini, et al.
Published: (2024-08-01)

Prognostic value of residual cancer burden after neoadjuvant chemotherapy in breast cancer: a comprehensive subtype-specific analysis
by: Soo-Young Lee, et al.
Published: (2025-04-01)

Deciphering riddles in molecular subtyping of bladder cancer
by: Yuxiao Li, et al.
Published: (2025-04-01)

Multimodal diagnostic models and subtype analysis for neoadjuvant therapy in breast cancer
by: Zheng Ye, et al.
Published: (2025-03-01)

The Relationship between Pathological Features and 18F-FDG PET/CT that Changed the Surgeon's Decision as Neoadjuvant Therapy in Breast Cancer
by: Akay Edizsoy, et al.
Published: (2022-06-01)

Cost-effectiveness of de-escalated molecular subtype dependent use of neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer in a Swedish setting
by: Sanjib Saha, et al.
Published: (2025-04-01)

Prognostic Importance of PTEN and P53 in Aggressive Luminal A Subtype Breast Cancers
by: Öykü Dila Gemci, et al.
Published: (2025-07-01)

Locoregional recurrence after neoadjuvant versus adjuvant chemotherapy based on tumor subtypes in patients with early-stage breast cancer: A multi-institutional retrospective cohort study
by: Jong-Ho Cheun, et al.
Published: (2024-12-01)

Molecular characterization and subtyping of Blastocystis in urticarial patients in Turkey
by: Merve Aydin, et al.
Published: (2019-01-01)

Impact of Neoadjuvant Chemotherapy (NAC) on Biomarker Expression in Breast Cancer
by: Suji Lee, et al.
Published: (2024-04-01)

The role of neoadjuvant chemotherapy before radical surgery in stage IB2/IIA2 squamous cell cervical cancers
by: Aysun ALCI, et al.
Published: (2024-06-01)

Does neoadjuvant chemotherapy reduce surgical complexity in patients with advanced-stage epithelial ovarian cancer?
by: Okan Aytekin, et al.
Published: (2024-07-01)

Prognostic Performance of the Residual Cancer Burden Index With Respect to Molecular Breast Cancer Subtypes
by: Emanuelle Narciso Alvarez Valente, et al.
Published: (2025-10-01)

Subtype distribution and molecular characterization of Blastocystis from hemodialysis patients in Turkey
by: Baris Gulhan, et al.
Published: (2020-12-01)

Evaluation of Ki67 Predictive Role and its Discordance Between Pretherapy Biopsy and Post therapy Surgical Specimen in breast cancer patients receiving neoadjuvant chemotherapy
by: Yasmin Moussa, et al.
Published: (2023-09-01)

EVALUATION OF KI67 PREDICTIVE ROLE AND ITS DISCORDANCE BETWEEN PRETHERAPY BIOPSY AND POST THERAPY SURGICAL SPECIMEN IN BREAST CANCER PATIENTS RECEIVING NEOADJUVANT CHEMOTHERAPY.
by: Dalia El Khodary, et al.
Published: (2023-09-01)

A prospective, phase II, neoadjuvant study based on chemotherapy sensitivity in HR+/HER2‐ breast cancer‐FINEST study
by: Li Chen, et al.
Published: (2025-04-01)

Value of early metabolic response for predicting axillary pathological complete response during neoadjuvant systemic therapy in triple negative and HER2-amplified breast cancers: impact of tumor subtypes
by: Loup Guichard, et al.
Published: (2025-09-01)

Neoadjuvant chemotherapy may be the best neoadjuvant therapy modality for non-metastatic pancreatic cancer: a population based study
by: Jie Yang, et al.
Published: (2024-04-01)

Does Apoptotic Index Predict the Response to Neoadjuvant Chemotherapy in Patients with Breast Carcinoma?
by: Gokce ASKAN, et al.
Published: (2023-03-01)

Editorial: Recent advancements in neoadjuvant chemotherapy for specific breast cancer subtypes
by: Sirin A. Adham, et al.
Published: (2022-12-01)

Influence of histopathological changes after neoadjuvant chemotherapy on the survival of breast cancer patients
by: Sabine Danzinger, et al.
Published: (2024-01-01)

Correlation of Histopathological and Radiological Response Patterns and Their Prognostic Implications in Breast Cancer After Neoadjuvant Chemotherapy
by: Bozer A, et al.
Published: (2024-12-01)

Blood levels of growth and progression factors in patients with locally advanced breast cancer during neoadjuvant chemotherapy
by: E. M. Frantsiyants, et al.
Published: (2021-09-01)

A randomized phase 3 trial of total neoadjuvant therapy (induction chemotherapy, neoadjuvant chemoradiation, neoadjuvant chemotherapy, and surgery) vs. standard long-term chemoradiation therapy (neoadjuvant chemoradiation, surgery, and adjuvant chemotherapy) in locally advanced rectal cancer
by: Freshte Foroughi, et al.
Published: (2024-12-01)

Neoadjuvant systemic therapy for patients with gastric cancer: Current concepts and outcomes
by: Fatih Selcukbiricik, et al.
Published: (2016-01-01)

Prognostic significance of T lymphocyte subgroups (CD4 and CD8) in lung cancer patients after neoadjuvant chemotherapy
by: Aykut Elicora, et al.
Published: (2024-03-01)

Pathological response of different molecular subtypes of locally advanced breast carcinoma to neoadjuvant chemotherapy
by: Nidhi Aley Alex, et al.
Published: (2023-08-01)

Neoadjuvant and Adjuvant Chemotherapy in Osteosarcoma (The Experience of HORC in the Shariati Hospital)
by: Alimoghadam K, et al.
Published: (2004-07-01)

Peripheral TNF-&alpha; and CD8+/CD28+ T Lymphocytes as Alternatives for PD-L1 Prediction in Breast Cancer Tumor Microenvironment: Stratified by Neoadjuvant Therapy
by: Wu J, et al.
Published: (2025-07-01)

Comparison of Standard Neoadjuvant Therapy and Total Neoadjuvant Therapy in Terms of Effectiveness in Patients Diagnosed with Locally Advanced Rectal Cancer
by: Ayberk Bayramgil, et al.
Published: (2025-02-01)

Neoadjuvant chemotherapy for colon cancer
by: M. Yu. Fedyanin, et al.
Published: (2022-06-01)

Transcriptomic signature defines two subtypes of locally advanced PCa with distinct neoadjuvant therapy benefits
by: Yinjie Zhu, et al.
Published: (2023-05-01)

The prognostic value of lymph node response to neoadjuvant therapy among breast cancer subtypes
by: Oana-Adriana RAJPUT-ANGHEL, et al.
Published: (2024-06-01)

Neoadjuvant and Adjuvant Chemotherapy in Osteosarcoma (The Experience of HORC in the Shariati Hospital)
by: K Alimoghadam, et al.
Published: (2004-03-01)